CIOFINI, SARA
 Distribuzione geografica
Continente #
EU - Europa 434
NA - Nord America 220
AS - Asia 36
AF - Africa 10
SA - Sud America 4
OC - Oceania 1
Totale 705
Nazione #
US - Stati Uniti d'America 218
IE - Irlanda 137
IT - Italia 125
GB - Regno Unito 65
SE - Svezia 38
FR - Francia 18
DE - Germania 17
FI - Finlandia 16
SG - Singapore 11
EG - Egitto 10
CN - Cina 6
NL - Olanda 6
IQ - Iraq 5
CZ - Repubblica Ceca 4
HK - Hong Kong 4
RU - Federazione Russa 4
BR - Brasile 3
IN - India 3
CA - Canada 2
JP - Giappone 2
AR - Argentina 1
AU - Australia 1
EE - Estonia 1
ES - Italia 1
KG - Kirghizistan 1
MK - Macedonia 1
MY - Malesia 1
RS - Serbia 1
SA - Arabia Saudita 1
TH - Thailandia 1
TW - Taiwan 1
Totale 705
Città #
Dublin 136
Southend 50
Ashburn 49
Chandler 47
Siena 25
Florence 21
Fairfield 14
Princeton 13
Helsinki 11
Milan 8
Seattle 8
Singapore 8
Woodbridge 8
Washington 7
New York 6
Lappeenranta 5
Wilmington 5
Cagliari 4
Cairo 4
Fremont 4
Houston 4
Ponte a Egola 4
Rome 4
Shanghai 4
Sulaymaniyah 4
Turin 4
Agnano 3
Bolzano 3
Brno 3
Cambridge 3
Genova 3
Islington 3
Modena 3
Paullo 3
Redditch 3
San Diego 3
The Hague 3
Ann Arbor 2
Beijing 2
Central 2
Frankfurt am Main 2
Hamburg 2
Hong Kong 2
Hyderabad 2
Livorno 2
London 2
Moscow 2
Poggibonsi 2
Reggio Emilia 2
Salvador 2
San Mateo 2
Sant'Agata di Puglia 2
Somma Vesuviana 2
Vicenza 2
Viterbo 2
Zagazig 2
Altopascio 1
Amsterdam 1
Baghdad 1
Bangkok 1
Barcelona 1
Bari 1
Bishkek 1
Boardman 1
Brixen 1
Buenos Aires 1
Cascina 1
Cortona 1
Groningen 1
Henderson 1
Los Angeles 1
Lucca 1
Markham 1
Monopoli 1
Monte San Savino 1
Mumbai 1
Naples 1
Nashville 1
New Bedfont 1
Prad am Stilfser Joch 1
Prescot 1
Riyadh 1
Sacramento 1
San Giovanni Valdarno 1
Sao Jose de Ribamar 1
Skopje 1
Southwark 1
Suez 1
Sydney 1
Taipei 1
Tallinn 1
Tanta 1
Toronto 1
Ōtemae 1
Totale 566
Nome #
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia 100
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 87
Anti CD38 monoclonal antibodies for multiple myeloma treatment 71
Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network) 68
New prognostic markers in acute myeloid lekemia: focus on BCL2 expression 66
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of FLT3-ITD in NPM1 mutated AML, irrespectively of FLT3-ITD allelic Burden 65
Monoclonal gammopathy of renal significance (MGRS): real-world data on outcomes and prognostic factors 61
Real-life experience with pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma: A retrospective and prospective study 42
Anti-BCMA novel therapies for multiple myeloma 33
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 31
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia 31
Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation 26
Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation 24
Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI 21
Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications 16
null 10
Totale 752
Categoria #
all - tutte 4.065
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.065


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202165 0 1 26 1 5 0 3 6 1 7 2 13
2021/2022103 2 5 6 13 2 4 5 4 3 19 16 24
2022/2023229 13 22 22 20 12 27 9 31 18 3 32 20
2023/2024342 12 9 38 30 14 68 97 15 5 15 9 30
2024/202513 13 0 0 0 0 0 0 0 0 0 0 0
Totale 752